{"id":"placebo-of-dutasteride-capsule","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances administered in controlled trials to establish baseline efficacy and safety profiles of the active drug being tested. In this case, it is a placebo matching the capsule formulation of dutasteride, a 5-alpha reductase inhibitor, but without the active ingredient. The placebo allows researchers to distinguish true drug effects from placebo response and natural disease progression.","oneSentence":"This is a placebo control formulation containing no active pharmaceutical ingredient, used as a comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:08.329Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04098302","phase":"PHASE2, PHASE3","title":"Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy","status":"COMPLETED","sponsor":"UConn Health","startDate":"2019-10-15","conditions":"Alcohol Use Disorder","enrollment":180},{"nctId":"NCT06916793","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-04-30","conditions":"Androgenetic Alopecia","enrollment":288},{"nctId":"NCT00668642","phase":"PHASE2","title":"Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2007-03","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT00082043","phase":"PHASE1","title":"Dutasteride to Treat Women With Menstrually Related Mood Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2004-03-31","conditions":"Premenstrual Syndrome, PMS, Healthy","enrollment":34},{"nctId":"NCT02058368","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-10","conditions":"Prostatic Hyperplasia","enrollment":607},{"nctId":"NCT02014584","phase":"PHASE3","title":"Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2014-07-02","conditions":"Alopecia","enrollment":117},{"nctId":"NCT01777269","phase":"PHASE4","title":"Prospective Sexual Function Study for BPH Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-18","conditions":"Prostatic Hyperplasia","enrollment":489},{"nctId":"NCT01262287","phase":"PHASE4","title":"Dutasteride for the Reduction of Alcohol Use in Male Drinkers","status":"COMPLETED","sponsor":"UConn Health","startDate":"2011-01","conditions":"Alcoholism, Alcohol Abuse, Alcohol Dependence","enrollment":47},{"nctId":"NCT00805701","phase":"PHASE4","title":"Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation","status":"COMPLETED","sponsor":"Bay State Clinical Trials, Inc.","startDate":"2009-01","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT00527605","phase":"PHASE3","title":"Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Benign Prostatic Hyperplasia, Prostatic Hyperplasia","enrollment":253},{"nctId":"NCT00558363","phase":"PHASE2","title":"ARTS - AVODART After Radical Therapy For Prostate Cancer Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Neoplasms, Prostate, Prostate Cancer After a Radical Treatment","enrollment":294}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Dutasteride Capsule","genericName":"Placebo of Dutasteride Capsule","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}